These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 1095689)

  • 1. Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias.
    Tarsy D; Parkes JD; Marsden CD
    J Neurol Neurosurg Psychiatry; 1975 Apr; 38(4):331-5. PubMed ID: 1095689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-alpha-methyldopa hydrazine (Carbidopa) combined with L-dopa in the treatment of Parkinson's disease.
    Glasgow GL; Henley JW; Willoughby EW
    Aust N Z J Med; 1974 Aug; 4(4):373-8. PubMed ID: 4278910
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter: Metoclopramide in parkinsonism.
    Tarsy D; Parkes JD; Marsden CD
    Lancet; 1975 May; 1(7918):1244-5. PubMed ID: 48872
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease.
    Lieberman A; Goodgold A; Jonas S; Leibowitz M
    Neurology; 1975 Oct; 25(10):911-6. PubMed ID: 1101099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tardive dyskinesia treated with pimozide.
    Claveria LE; Teychenne PF; Calne DB; Haskayne L; Petrie A; Pallis CA; Lodge-Patch IC
    J Neurol Sci; 1975 Apr; 24(4):393-401. PubMed ID: 235013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha methyldopahydrazine as an adjunct to levodopa therapy in Parkinson's disease.
    Paty DW; Jaatoul N; Kertesz A; McInnis W
    Can J Neurol Sci; 1975 Aug; 2(3):169-72. PubMed ID: 1100213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deanol in the treatment of levodopa-induced dyskinesias.
    Klawans HL; Topel JL; Bergen D
    Neurology; 1975 Mar; 25(3):290-3. PubMed ID: 1167639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [L-dopa-decarboxylase inhibitor combination preparation (Sinemet) in parkinsonism and syndromes imitating parkinsonism. 1 year's experience with 34 patients].
    Holmsen R
    Tidsskr Nor Laegeforen; 1976 Feb; 96(4):225, 234-6. PubMed ID: 1251394
    [No Abstract]   [Full Text] [Related]  

  • 9. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease.
    Langston JW; Ballard P
    Can J Neurol Sci; 1984 Feb; 11(1 Suppl):160-5. PubMed ID: 6608979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of combining carbidopa with levodopa for Parkinson's disease.
    Martin WE; Tolosa ES; Loewenson RB; Lee MC; Resch JA; Baker AB
    Geriatrics; 1975 Dec; 30(12):39-44. PubMed ID: 1104406
    [No Abstract]   [Full Text] [Related]  

  • 11. Increased dosage of carbidopa in patients with Parkinson's disease receiving low doses of levodopa. A pilot study.
    Hoehn MM
    Arch Neurol; 1980 Mar; 37(3):146-9. PubMed ID: 7356419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.
    Andrews CJ; Somerville B
    Med J Aust; 1974 Mar; 1(12):429-32. PubMed ID: 4598384
    [No Abstract]   [Full Text] [Related]  

  • 13. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
    Luquin MR; Scipioni O; Vaamonde J; Gershanik O; Obeso JA
    Mov Disord; 1992; 7(2):117-24. PubMed ID: 1350058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tiapride in levodopa-induced involuntary movements.
    Lees AJ; Lander CM; Stern GM
    J Neurol Neurosurg Psychiatry; 1979 Apr; 42(4):380-3. PubMed ID: 458486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A controlled study comparing trihexyphenidyl hydrochloride plus levodopa with placebo plus levodopa in patients with Parkinson's disease.
    Martin WE; Loewenson RB; Resch JA; Baker AB
    Neurology; 1974 Oct; 24(10):912-9. PubMed ID: 4606107
    [No Abstract]   [Full Text] [Related]  

  • 17. Madopar versus sinemet. A clinical study on their effectiveness.
    Korten JJ; Keyser A; Joosten EM; Gabreëls FJ
    Eur Neurol; 1975; 13(2):65-71. PubMed ID: 1095374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.
    Koller W; Guarnieri M; Hubble J; Rabinowicz AL; Silver D
    J Neural Transm (Vienna); 2005 Feb; 112(2):221-30. PubMed ID: 15503197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbidopa/levodopa therapy of coexistent drug-induced parkinsonism and tardive dyskinesia.
    Shoulson I
    Adv Neurol; 1983; 37():259-66. PubMed ID: 6134445
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.